Chintan Parekh, M.D.
Pediatric Hematology
- T Cell Development
- T Cell Immunotherapies
- Pediatric Leukemia
- Associate Professor, Department of Pediatrics
Chintan Parekh, M.D. is an associate clinical professor in the Department of Pediatrics at City of Hope® Cancer Center Duarte. He specializes in treating pediatric leukemia and conducting basic science laboratory research in the fields of T-cell immunotherapy, blood cell development and blood cancers. He chose to focus on pediatric care because of the profound impact that curing cancer has on a young person’s life.
As the director of the Chintan Parekh Lab at City of Hope, Dr. Parekh focuses his research on deciphering the molecular mechanisms driving normal human blood and immune cell development and understanding how errors in these mechanisms result in leukemia. The goals of his research lab are to apply the insights about immune cell mechanisms to the development of more effective anticancer immunotherapies and design new therapies targeting the errors underlying leukemia. Dr. Parekh’s research has revealed biological pathways driving normal human T-cell development.
His lab is currently investigating whether manipulating the activity of these pathways will yield more effective T cell immunotherapies for cancer. His research is funded by R01 grants from the National Institute of Health (NIH) and has resulted in publications in high-impact journals like Nature Immunology and Immunity. Dr. Parekh’s translational research portfolio includes the investigation of mechanisms underlying immune responses in patients via the study of immune cells collected from children and young adults undergoing immunotherapy.
In addition to being a member of the American Society of Hematology (ASH) and the Society for Pediatric Research, Dr. Parekh is a member of the ASH Scientific Committee for Immunology and Host Defense and has served as a grant reviewer for the NIH and several prestigious cancer research foundations.
After earning his medical degree at the Seth Gordhandas Sunderdas Medical College in Mumbai, India, Dr. Parekh completed residencies in pediatrics at Swansea NHS Trust in the United Kingdom and the Women & Children’s Hospital of Buffalo (now Oishei Children's Hospital) in New York state, followed by a fellowship in pediatric hematology-oncology at Children’s Hospital Los Angeles. Prior to joining City of Hope, Dr. Parekh was an associate professor of clinical pediatrics at the Keck School of Medicine at the University of Southern California in Los Angeles, California.
Location
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
Board Certifications
- 2007, American Board of Pediatrics, Maintenance of Certification (MOC) current
- 2011, American Board of Pediatric Hematology Oncology (MOC) current
Degrees
- 2003, M.B.B.S., Seth G.S. Medical College, Mumbai, India
Residencies
- 2003-2004, Residency, Pediatrics, Swansea NHS Trust, Swansea, United Kingdom
- 2004-2007, Residency, Pediatrics, Women and Children’s Hospital of Buffalo, Buffalo, NY
Fellowships
- 2007-2011, Fellowship, Pediatric Hematology-Oncology, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, CA
Professional Experience
- 2024-present, Associate Clinical Professor, Department of Pediatric, City of Hope, Duarte, CA
- 2022-2024, Associate Professor, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA
- 2012-2022, Assistant Professor, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA
- 2011-2012, Clinical Instructor, Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
Awards & Memberships
Memberships
- American Society of Hematology
- Society for Pediatric Research
Awards
- April 2019, Resident Teaching award, Children's Hospital Los Angeles, CA
- November 2019, Resident Teaching award, Children's Hospital Los Angeles, CA
Publications
- Ma J, Luong A, Doan A, Lin TY, Ji L, Wang CP, Yoon Sj, Rushing T, Duong A, Villa M, Parekh C. T-Cell Dysfunction during Blinatumomab Therapy in Pediatric Acute Lymphoblastic Leukemia. Blood Adv. 2025 Aug 12; doi: 10.1182/bloodadvances.2025015894
- Parker RS, Le J, Villa M, Luong A, Tsen YL, Lee Y, Doan A, Aguayo-Hiraldo P, Pannaraj PS, Yeon SJ, Wallace W, Armstrong A, O'Gorman MR, Dien Bard J, Parekh C. COVID-19 vaccinated Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia show Spike Protein reactive neutralizing antibodies and/or multifunctional T-cells. Int J Cancer. 2024 Jul 15. doi: 10.1002/ijc.35096.
- Gaynon PS, Parekh C. A new standard of care for childhood T-cell acute lymphoblastic leukemia? Pediatr Blood Cancer. 2021 Oct;68(10):e29238. doi: 10.1002/pbc.29238. Epub 2021 Jul 24. PubMed PMID: 34302711.
- Le J, Park JE, Ha VL, Luong A, Branciamore S, Rodin AS, Gogoshin G, Li F, Loh YHE, Camacho V, Patel SB, Welner RS, Parekh C. Single-Cell RNA-Seq Mapping of Human Thymopoiesis Reveals Lineage Specification Trajectories and a Commitment Spectrum in T Cell Development. Immunity. 52(6);1105-18, 2020. PMID: 32553173. PMCID: PMC7388724.
- Gang EJ., Kim HN, Hsieh YT, Ruan Y, Ogan, HA, Lee S, Pham J, Geng H, Park E, Klemm L, Willman CL, Carroll WL, Mittelman SD, Orgel E, Oberley MJ, Parekh C, Abdel-Azim H, Bhojwani D, Wayne AS, De Arcangelis A, Georges-Labouesse E, Wayner E, Bonig H, Minasyan A, Ten Hoeve J, Graeber TG, Müschen M, Heisterkamp N, Kim YM. Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia. Blood. 136(2):210-223, 2020. PMID: 32219444. PMCID: PMC7357190.
- Ha VL, Luong A, Casero D, Li F, Malvar J, Kim YM, Bhatia R, Crooks GM, Parekh C. The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation. Leukemia. 31(11):2503–14, 2017. PMID: 28232744 PMCID: PMC5599326.
- Moke DJ*, Oberley MJ, Bhojwani D, Parekh C** (co-last author), Orgel E**. Association of clinical trial enrollment and survival using contemporary therapy for pediatric acute lymphoblastic leukemia. Pediatric Blood and Cancer. 65(2):10.1002/pbc.26788, 2017. PMID: 28876513 PMCID: PMC7553364. ** These authors contributed equally to this work and are co-corresponding authors.
- Casero D, Sandoval S, Seet CS, Scholes J, Zhu Y, Ha VL, Luong A, Parekh C** (co-last author) and Crooks GM**. Global mapping and classification of long non-coding RNAs during human lymphoid commitment reveals transcriptional divergence of B and T lineages. Nature Immunology. 16(12):1282-91, 2015. PMID: 26502406 PMCID: PMC4653072. ** These authors contributed equally to this work and are co-corresponding authors.
- Parekh C, Gaynon PS, Abdel-Azim H. End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer 62(11):2040-3, 2015. PMID: 25976383 PMCID: PMC4583337.
- Kohn LA, Hao QL, Sasidharan R, Parekh C, Ge S, Zhu Y, Mikkola HKA, Crooks GM. Lymphoid priming in human bone marrow begins before expression of CD10 with up-Regulation of l-selectin. Nature Immunology. 13(10):963-71,2012. PMID: 22941246 PMCID: PMC3448017.